About Us Services Careers FAQ Contact Us 0
Home Medical Devices Next-Generation Gynecological Cancer Diagnostics Market Size, Trends, Share, to 2030
Next-Generation Gynecological Cancer Diagnostics Market

Next-Generation Gynecological Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next-Generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays), By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer), By Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRMD2096DR
Last Updated : September 05, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Next-Generation Gynecological Cancer Diagnostics Market Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    6. U.S.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Next-Generation Sequencing
          1. By Value
        3. qPCR & Multiplexing
          1. By Value
        4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
          1. By Value
        5. Protein Microarrays
          1. By Value
        6. DNA Microarrays
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Biomarker Development
          1. By Value
        3. CTC Analysis
          1. By Value
        4. Proteomic Analysis
          1. By Value
        5. Epigenetic Analysis
          1. By Value
        6. Genetic Analysis
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Cervical Cancer
          1. By Value
      4. By Function 
        1. Introduction
          1. Function  By Value
        2. Therapeutic Monitoring
          1. By Value
        3. Companion Diagnostics
          1. By Value
        4. Prognostics
          1. By Value
        5. Cancer Screening
          1. By Value
        6. Risk Analysis
          1. By Value
    7. Canada
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    6. U.K.
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Next-Generation Sequencing
          1. By Value
        3. qPCR & Multiplexing
          1. By Value
        4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
          1. By Value
        5. Protein Microarrays
          1. By Value
        6. DNA Microarrays
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Biomarker Development
          1. By Value
        3. CTC Analysis
          1. By Value
        4. Proteomic Analysis
          1. By Value
        5. Epigenetic Analysis
          1. By Value
        6. Genetic Analysis
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Cervical Cancer
          1. By Value
      4. By Function 
        1. Introduction
          1. Function  By Value
        2. Therapeutic Monitoring
          1. By Value
        3. Companion Diagnostics
          1. By Value
        4. Prognostics
          1. By Value
        5. Cancer Screening
          1. By Value
        6. Risk Analysis
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    6. China
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Next-Generation Sequencing
          1. By Value
        3. qPCR & Multiplexing
          1. By Value
        4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
          1. By Value
        5. Protein Microarrays
          1. By Value
        6. DNA Microarrays
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Biomarker Development
          1. By Value
        3. CTC Analysis
          1. By Value
        4. Proteomic Analysis
          1. By Value
        5. Epigenetic Analysis
          1. By Value
        6. Genetic Analysis
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Cervical Cancer
          1. By Value
      4. By Function 
        1. Introduction
          1. Function  By Value
        2. Therapeutic Monitoring
          1. By Value
        3. Companion Diagnostics
          1. By Value
        4. Prognostics
          1. By Value
        5. Cancer Screening
          1. By Value
        6. Risk Analysis
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    6. UAE
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Next-Generation Sequencing
          1. By Value
        3. qPCR & Multiplexing
          1. By Value
        4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
          1. By Value
        5. Protein Microarrays
          1. By Value
        6. DNA Microarrays
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Biomarker Development
          1. By Value
        3. CTC Analysis
          1. By Value
        4. Proteomic Analysis
          1. By Value
        5. Epigenetic Analysis
          1. By Value
        6. Genetic Analysis
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Cervical Cancer
          1. By Value
      4. By Function 
        1. Introduction
          1. Function  By Value
        2. Therapeutic Monitoring
          1. By Value
        3. Companion Diagnostics
          1. By Value
        4. Prognostics
          1. By Value
        5. Cancer Screening
          1. By Value
        6. Risk Analysis
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Technology
      1. Introduction
        1. Technology By Value
      2. Next-Generation Sequencing
        1. By Value
      3. qPCR & Multiplexing
        1. By Value
      4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        1. By Value
      5. Protein Microarrays
        1. By Value
      6. DNA Microarrays
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Biomarker Development
        1. By Value
      3. CTC Analysis
        1. By Value
      4. Proteomic Analysis
        1. By Value
      5. Epigenetic Analysis
        1. By Value
      6. Genetic Analysis
        1. By Value
    4. By Cancer Type
      1. Introduction
        1. Cancer Type By Value
      2. Lung Cancer
        1. By Value
      3. Breast Cancer
        1. By Value
      4. Colorectal Cancer
        1. By Value
      5. Cervical Cancer
        1. By Value
    5. By Function 
      1. Introduction
        1. Function  By Value
      2. Therapeutic Monitoring
        1. By Value
      3. Companion Diagnostics
        1. By Value
      4. Prognostics
        1. By Value
      5. Cancer Screening
        1. By Value
      6. Risk Analysis
        1. By Value
    6. Brazil
      1. By Technology
        1. Introduction
          1. Technology By Value
        2. Next-Generation Sequencing
          1. By Value
        3. qPCR & Multiplexing
          1. By Value
        4. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
          1. By Value
        5. Protein Microarrays
          1. By Value
        6. DNA Microarrays
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Biomarker Development
          1. By Value
        3. CTC Analysis
          1. By Value
        4. Proteomic Analysis
          1. By Value
        5. Epigenetic Analysis
          1. By Value
        6. Genetic Analysis
          1. By Value
      3. By Cancer Type
        1. Introduction
          1. Cancer Type By Value
        2. Lung Cancer
          1. By Value
        3. Breast Cancer
          1. By Value
        4. Colorectal Cancer
          1. By Value
        5. Cervical Cancer
          1. By Value
      4. By Function 
        1. Introduction
          1. Function  By Value
        2. Therapeutic Monitoring
          1. By Value
        3. Companion Diagnostics
          1. By Value
        4. Prognostics
          1. By Value
        5. Cancer Screening
          1. By Value
        6. Risk Analysis
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Next-Generation Gynecological Cancer Diagnostics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Agilent Technologies, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. ARUP Laboratories
    3. BGI Genomics
    4. CENTOGENE N.V.
    5. F. Hoffmann-La Roche Ltd
    6. Fulgent Genetics, Inc.
    7. Illumina, Inc.
    8. Invitae Corporation
    9. Konica Minolta, Inc.
    10. Laboratory Corporation of America Holdings
    11. Myriad Genetics, Inc.
    12. OPKO Health, Inc.
    13. QIAGEN N.V.
    14. Quest Diagnostics Incorporated
    15. Thermo Fisher Scientific Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global bispecific antibodies market size was valued at USD 8.2 billion in 2023 and is projected to reach a value of USD 224.6 billion by 2032, registering a CAGR of 44.4% during the forecast period (2024-2032). The rise in cancer incidence is a c
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.